July 12, 2022. Successful completion of non-clinical tissue cross reactivity study for the binder of T-CURX CAR-T cell pipeline product for AML patients

Favorable results obtained from non-clinical tissue cross-reactivity study with binder incorporated in T-CURX CAR-T cell pipeline program in AML

Today, T-CURX announces that a non-clinical tissue cross reactivity (TCR) study with the binder incorporated in T-CURX' CAR-T cell pipeline product for patients with Acute Myeloid Leukemia (AML), assessed on an FDA panel of healthy human tissues, showed the expected absence of expression in healthy human tissues.

This non-clinical study, outsourced to a blue-chip CRO, with strong know-how in these types of analyses, confirms the suitability of T-CURX' late-stage non-clinical CAR-T cell pipeline product in AML for the start of First-in-Human (FiH) clinical trials.